Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.70 |
| ▸ | MAOA | P21397 | 16/20 | 0.70 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585538 | 0.96 | MAOB (0.68) | MAOBMAOAPDE3BPDE3AHTR1A | |
| SCHEMBL6584817 | 0.94 | MAOB (0.67) | MAOBMAOAPDE3BPDE3AHTR1A | |
| SCHEMBL6583075 | 0.94 | MAOB (0.67) | MAOBMAOAPDE3BPDE3AHTR1A | |
| SCHEMBL6585388 | 0.92 | MAOB (0.60) | MAOBMAOAPDE3BPDE3AHTR1A | |
| SCHEMBL10674249 | 0.88 | MAOB (0.62) | MAOBMAOAPDE3BPDE3AHTR1A | |
| SCHEMBL12359302 | 0.88 | MAOB (0.70) | MAOBMAOAPDE3BPDE3AHTR1A | |
| SCHEMBL1040338 | 0.88 | MAOB (0.70) | MAOBMAOA | |
| SCHEMBL10675306 | 0.87 | MAOB (0.68) | MAOBMAOAPDE3BPDE3AHTR1A | |
| SCHEMBL9164057 | 0.87 | MAOB (0.68) | MAOBMAOAPDE3BPDE3AHTR1A | |
| SCHEMBL8212260 | 0.87 | MAOB (0.72) | MAOBMAOADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006301-B1 | And synthesis of dual 5-HT1A and 5-HT7 receptor ligands | FLORIDA A&M UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-RE48059-E1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9839637-B1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-20170231983-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| WO-2010090347-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-1869025-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006112464-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
| EP-0957100-B1 | DIAMINE DERIVATIVES AND PHARMACEUTICAL CONTAINING THE SAME | KOWA CO (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-0957100-A1 | DIAMINE DERIVATIVES AND PHARMACEUTICAL CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5541198-A | ANTISTICKING AGENTS FOR PLATELETS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-30 | — | — | US | disclosed |
| EP-0651747-B1 | CARBOSTYRYL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-03-27 | — | — | EP | disclosed |
| EP-0651747-A1 | CARBOSTYRIL DERIVATIVES. | OTSUKA PHARMA CO LTD (JP) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994026732-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885PDE3B 1824/4885 |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885PDE3B 1824/4885 |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885PDE3B 1824/4885 |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885PDE3B 1824/4885 |
| US-12006301-B1 | And synthesis of dual 5-HT1A and 5-HT7 receptor ligands | HTR7, HTR1A, HTR5A | MAOB 79/4885MAOA 38/4885PDE3B 837/4885 |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885PDE3B 1824/4885 |
| US-20170231983-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885PDE3B 1824/4885 |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885PDE3B 1824/4885 |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | MAOB 256/4885MAOA 411/4885PDE3B 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.